362 related articles for article (PubMed ID: 31690270)
21. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
22. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma.
Wright TM; Brannon AR; Gordan JD; Mikels AJ; Mitchell C; Chen S; Espinosa I; van de Rijn M; Pruthi R; Wallen E; Edwards L; Nusse R; Rathmell WK
Oncogene; 2009 Jul; 28(27):2513-23. PubMed ID: 19448672
[TBL] [Abstract][Full Text] [Related]
23. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
[TBL] [Abstract][Full Text] [Related]
24. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
Sinha S; Dwivedi N; Tao S; Jamadar A; Kakade VR; Neil MO; Weiss RH; Enders J; Calvet JP; Thomas SM; Rao R
Oncogene; 2020 Feb; 39(6):1231-1245. PubMed ID: 31616061
[TBL] [Abstract][Full Text] [Related]
25. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
[TBL] [Abstract][Full Text] [Related]
26. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
[TBL] [Abstract][Full Text] [Related]
27. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
[TBL] [Abstract][Full Text] [Related]
28. Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma.
Yao X; Qi L; Chen X; Du J; Zhang Z; Liu S
Urol Oncol; 2014 Feb; 32(2):162-70. PubMed ID: 23570708
[TBL] [Abstract][Full Text] [Related]
29. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
30. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
31. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
[TBL] [Abstract][Full Text] [Related]
32. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.
Morikawa T; Sugiyama A; Kume H; Ota S; Kashima T; Tomita K; Kitamura T; Kodama T; Fukayama M; Aburatani H
Clin Cancer Res; 2007 Oct; 13(19):5703-9. PubMed ID: 17908959
[TBL] [Abstract][Full Text] [Related]
33. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
[TBL] [Abstract][Full Text] [Related]
34. The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.
Komohara Y; Morita T; Annan DA; Horlad H; Ohnishi K; Yamada S; Nakayama T; Kitada S; Suzu S; Kinoshita I; Dosaka-Akita H; Akashi K; Takeya M; Jinushi M
Cancer Immunol Res; 2015 Sep; 3(9):999-1007. PubMed ID: 25783986
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
36. High RSK4 expression constitutes a predictor of poor prognosis for patients with clear cell renal carcinoma.
Ma J; Wang K; Chai J; Xu T; Wei J; Liu Y; Wang Y; Xu J; Li M; Fan L
Pathol Res Pract; 2021 Nov; 227():153642. PubMed ID: 34649054
[TBL] [Abstract][Full Text] [Related]
37. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
Gockel I; Moehler M; Frerichs K; Drescher D; Trinh TT; Duenschede F; Borschitz T; Schimanski K; Biesterfeld S; Herzer K; Galle PR; Lang H; Junginger T; Schimanski CC
Oncol Rep; 2008 Oct; 20(4):845-50. PubMed ID: 18813825
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas.
Lee YM; Kim JM; Lee HJ; Seong IO; Kim KH
Urol Oncol; 2019 Oct; 37(10):742-748. PubMed ID: 31053527
[TBL] [Abstract][Full Text] [Related]
39. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma.
García-Alonso S; Romero-Pérez I; Gandullo-Sánchez L; Chinchilla L; Ocaña A; Montero JC; Pandiella A
J Exp Clin Cancer Res; 2021 Aug; 40(1):256. PubMed ID: 34399807
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P
Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
